U.S. Supreme Court Releases Decision in Chemical Abortion Case
Today, the U.S. Supreme Court released its unanimous decision that the Alliance for Hippocratic Medicine, et al, did not have standing in its case against the Food and Drug Administration (FDA). If you listened to oral argument back in March, you would have noticed that the majority of time was spent on standing.
What does this mean?
The merits of the case were not addressed. Because the plaintiffs were deemed not to have standing, the Court did not address the reckless behavior of the FDA from initial approval of the deadly and dangerous abortion drug Mifepristone in 2000 to the protocol changes it has made to the abortion drug regimen through 2023:
2000: FDA approves the chemical abortion deadly duo of Mifepristone and misoprostol by characterizing pregnancy as an “illness.” FDA allows usage for up to 7 weeks of pregnancy, requires 3 doctor’s visits, and requires reporting of all adverse events.
2011: FDA brings Mifepristone under REMS (Risk Evaluation and Mitigation Strategy.) Per FDA, REMS is a “drug safety program that the U.S. Food and Drug Administration (FDA) can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks.”
2016: FDA modifies protocol, changes dosages, drops doctor visit requirements from 3 to 1, extends time limit from 7 to 10 weeks, expands prescriber pool allowing non-doctors to prescribe this high-risk medication, changes adverse event reporting from all events, to death only.
2021: FDA announces permanent suspension of in-person doctor visit requirement; adds pharmacy distribution, announced it would no longer enforce the initial in-person doctor visit and approved medication by mail.
2023: FDA announces official modification of REMS, eliminates in-person distribution requirement, defines certification process for pharmacy distribution.
On a positive note…
Anyone who reads the opinion can read for themselves some of the changes the FDA has made since 2000. If the media is honest, they will publish this information straight from the Court to help inform women about the changes and the risks.
Secondly, it appears that anyone with court-defined standing can still file a case.
Finally, by no means is the fight over. The fight is multi-faceted. The case will now return to district court where the Attorneys General of Idaho, Kansas and Missouri will be challenging the FDA based on harm to women in their states.
It can’t be over in Georgia either.
Per Big Abortion’s own reporting organization, Guttmacher Institute, recently reported that chemical abortions are now up to 63% of all abortions nationwide. In Georgia, when the new abortion numbers are released, we anticipate chemical abortions to be over 80% of all abortions.
This is why this case was so important in saving the lives of Georgians.
